Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. - Wikidata - wikimedia - TriplyDB

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

http://www.wikidata.org/entity/Q34648995

about

Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?KASL clinical practice guidelines: management of hepatitis C Programmed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapy Antiviral treatment of hepatitis C virus infection and factors affecting efficacy Update on the treatment of patients with non-genotype 1 hepatitis C virus infection Liver safety assessment in special populations (hepatitis B, C, and oncology trials)Evaluation of an Automated Nucleic Acid Extractor for Hepatitis C Virus Load Quantification A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients Performance of the Abbott Real-Time PCR Assay Using m2000sp and m2000rt for Hepatitis C Virus RNA Quantification Treatment responses in Asians and Caucasians with chronic hepatitis C infection The Evolution of the Major Hepatitis C Genotypes Correlates with Clinical Response to Interferon Therapy Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population Expert opinion on the treatment of patients with chronic hepatitis C Rate of Sustained Virologic Response in Relation to Baseline Hepatitis C Virus (HCV) RNA Level and Rapid Virologic Clearance in Persons with Acute HCV Infection Four-week pegylated interferon a-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A Protease Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3 Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study Diagnosis, management, and treatment of hepatitis C: an update Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents Current challenges in viral hepatitis, antimicrobial resistance and the influenza pandemic.Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large Individualisation of antiviral therapy for chronic hepatitis C.High rates of early treatment discontinuation in hepatitis C-infected US veterans.Random effect model for identifying related factors to virological response in HCV patients The hepatitis C cascade of care: identifying priorities to improve clinical outcomes Hepatitis C in Argentina: epidemiology and treatment.Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.Optimizing the dose and duration of therapy for chronic hepatitis C.A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations.Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study.Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response.Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

P2860

Q24644729-299222EA-F87A-425E-AE7A-FBCBBB820F7D Q26752471-CCF3F43A-1FE3-4970-8391-E24F31057C50 Q26781481-59E337C7-EB3C-44A5-BD7C-243F859B1DA1 Q26851810-60ECA6B9-C7F9-448E-BAE7-B69A6679E4C1 Q27000806-A67EB2D0-2EFB-4E38-8A26-3444C49AB355 Q27008502-03F9D8E1-2A9F-413D-A5BD-46243A261D49 Q27487980-80667CA1-5E5F-41C3-B007-4BD6B144A768 Q27487985-B1A2DAE8-7686-4C34-B303-F8E6816FE1B5 Q27488563-CE3E8B4B-CCA6-45E0-A8E9-9548449DD259 Q27489011-4906C5F8-2499-4F76-AB07-9D1F7DBABE5A Q27489040-B1BA6F72-33FA-4C2C-8B6E-D114D48B64B8 Q27489667-9DE1ECF0-7E2B-444F-AC13-99ED8537AFED Q27489903-1F16FB33-579C-4BEB-9C29-E6364E008E94 Q27490171-75C2206C-B701-4F62-AB7B-CACE443B7B0A Q27490396-17C49AB5-22BC-41AB-BC2B-2D5CD1B5C26B Q27490545-D96F220B-17ED-4877-99B7-1A0080EC809C Q27490841-50ED0256-AF3C-4BC1-A647-98766D8DEE65 Q27491047-633D8D83-8867-40F5-8DB0-D5FCDD81C057 Q28070260-47EE03DE-7114-46D3-92C6-84F1E57B6D81 Q28080225-8191A2DE-95D7-4A92-8758-25748BC9297E Q28543090-A9997A1C-B3E5-4F33-9C8C-B9CFFB6005A7 Q28546936-D3E42823-7779-46CA-98D1-E7898ECF5530 Q29619682-800F9259-BBE5-4533-9493-4FD47F807DA8 Q30151392-045823CD-7B16-40CD-BE06-9F6BB334C84E Q30365599-B6B2BF1C-4B89-4359-9289-04D5CBBA6206 Q30381336-B6EFA020-8859-437A-9BDA-6F348ECFABCD Q31121312-0340CA27-DF9C-4892-BF25-700DF8CB8C39 Q33390478-CE78DA61-5CA4-4FBC-910D-6818D00105B3 Q33574602-8B44E81C-3FBF-4373-BA67-7DA1B70EB200 Q33596718-7348E9E9-6976-42A0-9E0D-13F3A41FB91A Q33632459-072049A4-3677-461A-B1E5-1E2E0D76FD82 Q33706886-99F90D16-81AB-4636-9A47-8CF0099D4245 Q33816657-3FE711E4-0F56-497D-9839-49724E280A70 Q33855483-C23B79AA-8E04-4AF6-831C-59067DFEFF88 Q33906157-3F1BA867-7684-4579-978D-EA8691C21847 Q33938574-4650CB09-14D0-4306-9305-6A0A6CC56520 Q33945882-9BEB0341-EAF9-469C-BA82-C3E593D60A90 Q33956478-E57DB10A-36EC-45D2-A650-B88D9E4BEF40 Q34007851-5919EB57-D48E-4B6F-9ABB-1328A4429961 Q34088623-705A0B79-895F-4361-906A-972180DE3B47

P2860

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

http://www.wikidata.org/entity/Q34648995

description

2007 nî lūn-bûn

@nan

2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

name

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@ast

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@en

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@nl

type

label

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@ast

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@en

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@nl

prefLabel

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@ast

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@en

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@nl

P1433

Q34648995-E8784ECF-2FC9-45B1-9143-38E148245DE9

P1476

Q34648995-475F09D4-F473-4717-8418-FAF075373F4F

P2093

Q34648995-0E7697F7-0410-4455-80AE-5FA42ECFEC43

Q34648995-17CD6DAC-1837-420B-A5F4-83198313BD2F

Q34648995-58270199-FF57-4FB6-974F-E77086E2189C

Q34648995-6457B89C-7F8C-4C98-B4D1-1CCDC590BD61

Q34648995-714016AB-840B-4229-8214-F34D3EED8A98

Q34648995-9ADD142E-95A1-4F5E-A966-1A89C30C53BF

Q34648995-A646226D-0F08-45EB-9A5D-F07DE9725F5C

Q34648995-A96B491D-1B35-439D-B2A3-902B28CD414F

Q34648995-A9CCF1F0-80C5-4A7D-9A50-F65CAB5303A3

Q34648995-B09D29F2-6C3E-4268-9D1F-3B8E7428DF3B

P304

Q34648995-ECDACEDE-F871-41C0-B1A0-463703F45640

P31

Q34648995-32C7A322-879C-4568-9EE1-3453B6D6FA74

P356

Q34648995-FED97102-1355-46BC-9196-80F83CB8525E

P407

Q34648995-1CE73363-6D0F-4B8B-8777-C6A34ACD258B

P433

Q34648995-5AF209C9-E0C5-498C-8AF1-F77FF0D6098B

P478

Q34648995-532E5026-5597-4EFF-8FA2-16F85E33A9F0

P50

Q34648995-7E1786FB-A74D-4C05-A3E1-CD983648F388

P577

Q34648995-AD78746D-73CE-42BE-A954-E18EEEE5968B

P698

Q34648995-5A27C01E-E0FE-42A0-8E98-44BD31FF1FED

P356

P1433

The New England Journal of Medicine

P1476

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

@en

P2093

ACCELERATE Investigators

http://www.w3.org/2001/XMLSchema#string

Amy Lin

http://www.w3.org/2001/XMLSchema#string

Ash Soman

http://www.w3.org/2001/XMLSchema#string

Bruce R Bacon

http://www.w3.org/2001/XMLSchema#string

David Nelson

http://www.w3.org/2001/XMLSchema#string

Fredy Suter

http://www.w3.org/2001/XMLSchema#string

Hugh Harley

http://www.w3.org/2001/XMLSchema#string

Karl Barange

http://www.w3.org/2001/XMLSchema#string

Mitchell L Shiffman

http://www.w3.org/2001/XMLSchema#string

Ricard Solá

http://www.w3.org/2001/XMLSchema#string

P304

124-134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA066403

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17625124

http://www.w3.org/2001/XMLSchema#string